Assistant Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Robert Wesolowski, MD
|
|
Give Review
Robert Wesolowski works in the field of Oncology. He researched medicine at State University of New York Downstate Medical Center College of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Robert Wesolowski, MD is a published MD as well. He has 25 publications published. The latest was: Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment. Doctor Robert Wesolowski, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Myeloid-derived suppressor Cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.
- Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
- Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A...
- Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast Cancer.
- Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer.
- Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
- Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
- A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast Cancer.
- Treatment-Related Mortality With Everolimus in Cancer Patients.
- Primary prevention of Cancer-related thrombosis: Special focus on ambulatory patients.
- Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
- Myeloid-derived suppressor cells in breast Cancer.
- Docetaxel-induced skin toxicities in breast Cancer patients subsequent to paclitaxel shortage: a case series and literature review.
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast Cancer.
- Gene expression profiling: changing face of breast Cancer classification and management.
- Chemotherapy for advanced Adrenal cancer: improvement from a molecular approach?
- Specific kinesin expression profiles associated with taxane resistance in basal-like breast Cancer.
- A young woman with a Breast mass: What every internist should know.
- Use of chemotherapy for patients with bone and soft-tissue sarcomas.
- Successful treatment of Hodgkin Lymphoma and acute leukemia.
- Is there a role for second-line chemotherapy in advanced gastric Cancer?
- Phase I trial of weekly docetaxel, weekly doxorubicin, daily Oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
- Neoadjuvant therapy for breast Cancer: assessing treatment progress and managing poor responders.
- Phenoxodiol: isoflavone Analog with antineoplastic activity.
Schools
Suny Downstate Medical Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Golden Rule
- Humana
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Cleveland Clinic Foundation -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1821264623 | |
| NPPES Provider LastName | WESOLOWSKI | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 43210 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 408.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821264623 |
| Last Name Of The Provider | WESOLOWSKI |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Thomas J. Sweeney, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Kari L. Kendra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert A. Baiocchi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Cassandra N. Grenade, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Goldberg, MD |
|
Dr. Charles F. Von Gunten, MD |
|
|
Dr. Samantha M. Jaglowski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jeanna L. Knoble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Woyach, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|